(thirdQuint)High Dose Oral 4-Aminosalicylic Acid (PASER) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children.

 Eligible pediatric patients with acute flares of ileocecal Crohn's disease will be randomized to receive either PASER(R), an approved delayed-release oral formulation of 4-aminosalicylic acid, in doses of 50 milligrams per kilogram three times daily for 2 weeks followed by 50 milligrams per kilogram twice daily for 2 weeks, or an identical-appearing placebo preparation.

 Patients will be required to maintain a daily diary and to return at 2 weeks for blood and stool tests.

 At the four week mark, patients will return for clinical evaluation, global assessment of disease activity and change in disease activity, as well as additional laboratory tests.

.

 High Dose Oral 4-Aminosalicylic Acid (PASER) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children@highlight

The purpose of this 4 week study is to determine whether PASER(R), an approved delayed-release oral formulation of 4-aminosalicylic acid, in doses of 50 milligrams per kilogram three times daily for 2 weeks followed by 50 milligrams per kilogram twice daily for 2 weeks, will resolve an acute flare of ileocecal Crohn's disease.

